artículo académico

• Regulatory T Cells Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells.  Immunity.  52:151-166. 2020
• Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.  Cancer Cell.  33:649-663. 2018
• Mechanism informs precision: In vivo determinants of response to anti-CTLA-4 antibodies.  Annals of Oncology.  29:v35-v36. 2018
• Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.  Immunity.  46:577-586. 2017
• The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2.  Molecular Cell.  65:730-742. 2017
• Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop.  Oncoimmunology.  5:e1186323. 2016
• TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors.  Cancer Research .  76:2087-2093. 2016
• CMV promotes recipient T-cell immunity following reduced-intensity T-cell - Depleted HSCT, significantly modulating chimerism status.  Blood.  125:731-739. 2015
• Fcγ-receptor tag team boosts anti-tumor immunity.  Trends Immunology.  36:388-389. 2015
• A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice.  Oncotarget.  5:7843-7857. 2014
• Anticomplementary activity of horse IgG and F(ab')2 antivenoms.  American Journal of Tropical Medicine and Hygiene.  90:574-584. 2014
• Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies.  Trends Immunology.  35:290-298. 2014
• Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?.  Journal of OncoImmunology.  2:e26148. 2013
• Cytomegalovirus Drives Mixed Chimerism Following T-Cell Depleted Allogeneic HSCT, Providing Protective Immunity In The Absence Of GvHD.  Blood.  122:4524-4524. 2013
• Immune modulation by genetic modification of dendritic cells with lentiviral vectors.  Virus Research.  176:1-15. 2013
• Lentiviral vector followed by protein immunisation breaks tolerance against the self‐antigen Her1 and results in lung cancer immunotherapy.  The Journal of Gene Medicine.  14:151-157. 2012
• PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy.  Oncoimmunology.  1:86-88. 2012
• On the Mechanism of T cell receptor down-modulation and its physiological significance.  The Journal of Bioscience and Medicine.  1:1-5. 2011
• PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8 + T cells.  EMBO Molecular Medicine.  3:581-592. 2011
• Selective Activation of Intracellular Signalling Pathways In Dendritic Cells For Cancer Immunotherapy.  Anti-cancer Agents in Medicinal Chemistry.  12:29-39. 2011
• Selective ERK Activation Differentiates Mouse and Human Tolerogenic Dendritic Cells, Expands Antigen-Specific Regulatory T Cells, and Suppresses Experimental Inflammatory Arthritis.  Arthritis & Rheumatology.  63:84-95. 2011
• Targeting Lentiviral Vectors for Cancer Immunotherapy.  Current Cancer Therapy Reviews.  7:248-260. 2011
• HIV-1 Lentiviral vector immunogenicity is mediated by Toll-Like Receptor 3 (TLR3) and TLR7.  Journal of Virology.  84:5627-5636. 2010
• Hypochlorous Acid: A Natural Adjuvant That Facilitates Antigen Processing, Cross-Priming, and the Induction of Adaptive Immunity.  The Journal of Immunology.  184:824-835. 2009
• Lentiviral Vectors Transduce Proliferating Dendritic Cell Precursors Leading to Persistent Antigen Presentation and Immunization.  Molecular Therapy.  17:1643-1650. 2009
• Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.  Biomedicine & Pharmacotherapy.  61:347-355. 2007
• Apoptotic events induced by naturally occurring retinoids ATRA and 13-cis retinoic acid on human hepatoma cell lines Hep3B and HepG2.  Cancer Letters.  229:271-281. 2005